新型高选择性α1A- 肾上腺素受体阻滞剂赛洛多辛治疗良性前列腺增生的临床应用

doi:10.3969/j.issn.1672-3384.2015.02.006

摘要
图/表
参考文献
相关文章 (14)

全文: PDF (1223 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：综述高选择性α1A- 肾上腺素受体阻滞剂赛洛多辛在良性前列腺增生（benign prostatic hyperplasia,BPH）治疗中的应用和最新研究进展。方法：检索国内外文献，对文献信息进行系统性分析，总结赛洛多辛的药理学特性和临床应用进展。结果与结论：赛洛多辛对α1A- 肾上腺素受体的选择性远高于α1B- 肾上腺素受体；赛洛多辛可快速、有效改善BPH 患者的国际前列腺症状评分（international prostate symptom score, IPSS）以及最大尿流率（maximum flow rate, Qmax）；赛洛多辛总体耐受性良好，心血管不良反应轻微。赛洛多辛的临床应用为快速、高效、安全改善BPH患者下尿路症状（lower urinary tract symptoms, LUTS）、提高BPH 患者生活质量提供了治疗新选择。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	那彦群

关键词 ：赛洛多辛, 良性前列腺增生, 临床应用

Abstract：Objective: To review the application and the latest development of silodosin which is a highly selective α1A-AR antagonist in the treatment of benign prostatic hyperplasia (BPH). Methods: Multiple databases were searched for the term ‘‘silodosin’’, and a systematic analysis was conducted to review the pharmacological characteristics and the clinical application of silodosin. Results and conclusion: Silodosin has a much higher selectivity to α1A-AR subtype than α1B-AR subtype. Silodosin can improve the BPH patients’ international prostate symptom score (IPSS) and maximum flow rate (Qmax) rapidly. Silodosin is generally well tolerated and is associated with minimal cardiovascular adverse effects. Silodosin provides a new therapeutic selection to improve lower urinary tract symptoms (LUTS) and quality of life of BPH patients.

Key words： silodosin benign prostatic hyperplasia clinical application

收稿日期: 2014-12-22

:	R971.94
	R711.3

引用本文:

那彦群. 新型高选择性α1A- 肾上腺素受体阻滞剂赛洛多辛治疗良性前列腺增生的临床应用[J]. 临床药物治疗杂志, 2015, 13(2): 24-28.
NA Yan-qun. Clinical application of highly selective α1A-AR antagonist silodosin in benign prostatic hyperplasia. CLINICAL MEDICATION JOURNAL, 2015, 13(2): 24-28.

链接本文:

http://www.lcywzlzz.com/CN/10.3969/j.issn.1672-3384.2015.02.006 或 http://www.lcywzlzz.com/CN/Y2015/V13/I2/24

[1] Parsons J K. Commentary on BPH and public health-have we lost the forest through the trees?[J]. J Urol, 2008, 179(5 Suppl): S81.
[2] 那彦群, 叶章群, 孙颖浩, 等. 中国泌尿外科疾病诊断治疗指南[M]. 北京：人民卫生出版社, 2014:245-266.
[3] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society[J].Am J Obstet Gynecol, 2002, 187(1): 116-126.
[4] Nickel J C, Mendez-Probst C E, Whelan T F, et al. 2010 Update:Guidelines for the management of benign prostatic hyperplasia[J].Can Urol Assoc J, 2010, 4(5): 310-316.
[5] Lepor H, Kazzazi A, Djavan B. α-blockers for benign prostatic hyperplasia: the new era[J]. Curr Opin Urol, 2012, 22(1): 7-15.
[6] Guimaraes S, Moura D. Vascular adrenoceptors: an update[J].Pharmacol Rev, 2001, 53(2): 319-356.
[7] Michel M C. The pharmacological profile of the α1A-adrenoceptor antagonist silodosin[J]. Eur Urol Suppl, 2010, 9(4): 486-490.
[8] Roehrborn C G, Schwinn D A. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia[J]. J Urol, 2004,171(3): 1029-1035.
[9] Yoshida M, Homma Y, Kawabe K. Silodosin, a novel selective α1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia[J]. Expert Opin Investig Drugs, 2007,16(12):1955-1965.
[10] Murata S, Taniguchi T, Takahashi M, et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature[J]. J Urol, 2000, 164(2): 578-583.
[11] Shibata K, Foglar R, Horie K, et al. KMD-3213, a novel, potent, α1Aadrenoceptor-selective antagonist: characterization using recombinant human α1-adrenoceptors and native tissues[J]. Mol Pharmacol,1995, 48(2): 250-258.
[12] Morishima S, Suzuki F, Nishimune A, et al. Visualization and tissue distribution of α1L-adrenoceptor in human prostate by the fluorescently labeled ligand Alexa-488-silodosin[J]. J Urol, 2010,183(2): 812-819.
[13] Tatemichi S, Kobayashi K, Maezawa A, et al. α1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213) [J].Yakugaku Zasshi ,2006, 126:209-216.
[14] Yamada S, Okura T, Kimura R. In vivo demonstration of α1Aadrenoceptor subtype selectivity of KMD-3213 in rat tis sues[J].J Pharmacol Exp Ther, 2001, 296(1): 160-167.
[15] Watson Laboratories Inc. US prescribing information: Rapaflo?(Silodosin) [EB/OL].(2014-04-07)[2014-11-02]. http://www.watson.com
[16] European Medicines Agency. Summary of product characteristics:Urorec? (Silodosin) [EB/OL].(2014-10-08)[2014-11-02]. http://www.ema.europa.eu.
[17] Daiichi Sankyo (China) Holdings Co., LTD. China Package Insert information: Urief? (Silodosin) [EB/OL].(2014-10-02)[2014-11-02].http://www. daiichisankyo.com.cn
[18] Kawabe K, Yoshida M, Homma Y, et al. Silodosin, a new alpha1Aadrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled,double-blind study in Japanese men[J]. BJU Int, 2006, 98(5):1019-1024.
[19] Marks L S, Gittelman M C, Hill L A, et al. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies[J]. J Urol, 2013, 189(1 Suppl): S122-128.
[20] Chapple C R, Montorsi F, Tammela T L, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind,placebo- and active-controlled clinical trial performed in Europe[J].Eur Urol, 2011, 59(3): 342-352.
[21] 李宁忱, 宋毅, 丁强, 等. 赛洛多辛治疗良性前列腺增生的随机双盲安慰剂对照多中心III 期临床研究[J]. 中华泌尿外科杂志,2013, 34(4): 305-309.
[22] Miyakita H, Yokoyama E, Onodera Y, et al. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia[J]. Int J Urol, 2010, 17(10): 869-875.
[23] Moon K H, Song P H, Yang D Y, et al. Efficacy and safety of the selective α1A-Adrenoceptor blocker silodosin for severe lower urinary tract symptoms associated with benign prostatic hyperplasia:a prospective, single-open-aabel, multicenter study in Korea[J].Korean J Urol, 2014, 55(5): 335-340.
[24] Kaplan S A, Roehrborn C G, Hill L A, et al. Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter?[J]. Open Access J Urol, 2011, 3:89-93.
[25] Takao T, Tsujimura A, Kiuchi H, et al. Improvement of nocturia and sleep disturbance by silodosin in male patients with lower urinary tract symptoms[J]. Int J Urol, 2015, 22(2):236-238.
[26] Kim T N, Nam J K, Lee K S, et al. Reasons for prescription change of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia[J]. Urology, 2014, 84(2): 427-432.
[27] Lepor H, Hill L A. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability[J].Pharmacotherapy, 2010, 30(12): 1303-1312.
[28] Yu H J, Lin A T, Yang S S, et al. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)[J]. BJU Int, 2011, 108(11):1843-1848.
[29] Chapple C R, Montorsi F, Tammela T L, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind,placebo- and active-controlled clinical trial performed in Europe[J].Eur Urol, 2011, 59(3): 342-352.
[30] Kalplan S A. Side effect of α-blocker use: retrograde ejaculation[J].Rev Urol, 2009, 11(1): S14-18.
[31] Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis[J]. J Sex Med, 2014, 11(6):1554-1566.